Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Bennett

Showing results (241-250 of 253) with videos related to

Pageof 26
Sort By:
Plos Biology|October 3, 2013
Hypoxic regulation of hand1 controls the fetal-neonatal switch in cardiac metabolismRoss A Breckenridge, Izabela Piotrowska, Keat-Eng Ng, et al.
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.
Journal of Medicinal Chemistry|March 29, 2011
Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamideLuke Zehnder, Michael Bennett, Jerry Meng, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 27, 2018
Real-World Safety and Efficacy of Fluid-Filled Dual Intragastric Balloon for Weight LossAbhishek Agnihotri, Amy Xie, Christopher Bartalos, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
JAMA|May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infectionFred Poordad, William Sievert, Lindsay Mollison, et al.
The Journal of Molecular Diagnostics : JMD|July 1, 2018
Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal CancerIván Prieto-Potin, Clara Montagut, Beatriz Bellosillo, et al.
JHEP Reports : Innovation in Hepatology|March 21, 2024
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responsesMan-Fung Yuen, Scott Fung, Xiaoli Ma, et al.
Journal of Hepatology|April 23, 2022
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infectionMan-Fung Yuen, Kosh Agarwal, Xiaoli Ma, et al.
Journal of Hepatology|June 13, 2022
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infectionMark S Sulkowski, Kosh Agarwal, Xiaoli Ma, et al.
Pageof 26

Showing results (241-250 of 253) with videos related to

Sort By:
Pageof 26
Plos Biology|October 3, 2013
Hypoxic regulation of hand1 controls the fetal-neonatal switch in cardiac metabolismRoss A Breckenridge, Izabela Piotrowska, Keat-Eng Ng, et al.
The New England Journal of Medicine|April 24, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsIra M Jacobson, Stuart C Gordon, Kris V Kowdley, et al.
Journal of Medicinal Chemistry|March 29, 2011
Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamideLuke Zehnder, Michael Bennett, Jerry Meng, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 27, 2018
Real-World Safety and Efficacy of Fluid-Filled Dual Intragastric Balloon for Weight LossAbhishek Agnihotri, Amy Xie, Christopher Bartalos, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
JAMA|May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infectionFred Poordad, William Sievert, Lindsay Mollison, et al.
The Journal of Molecular Diagnostics : JMD|July 1, 2018
Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal CancerIván Prieto-Potin, Clara Montagut, Beatriz Bellosillo, et al.
JHEP Reports : Innovation in Hepatology|March 21, 2024
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responsesMan-Fung Yuen, Scott Fung, Xiaoli Ma, et al.
Journal of Hepatology|April 23, 2022
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infectionMan-Fung Yuen, Kosh Agarwal, Xiaoli Ma, et al.
Journal of Hepatology|June 13, 2022
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infectionMark S Sulkowski, Kosh Agarwal, Xiaoli Ma, et al.
Pageof 26